检索结果-南通市图书馆

Expression of cyclooxygenase in hyperdynamic portal hypertensive rats

Hepatobiliary & Pancreatic Diseases International 2006年第2期5卷 252-256页

作者： hui cao, jia xu, rong hua, fang-bin meng, jiang-feng qiu and zhi-yong wu department of surgery, renji hospital, shanghai second medical university, shanghai 200127, china department of surgery Renji Hospital Shanghai Second Medical University Shanghai 200127 China.

BACKGROUND: By detecting hemodynamic changes, concentration of plasm prostacyclin ( PGI2) and expression of cyclooxygenase( COX) in vasculature and splanchnic tissues, we evaluated the relative contributions of PGI2 and COX mRNA expression to the hyperdynamic circulatory state in chronic portal hypertensive rats. METHODS: Fifty male Sprague-Dawley rats were divided into 3 groups: intrahepatic portal hypertension (IHPH, n = 18) by injection of CCl4, prehepatic portal hypertension (PHPH, n = 18) by partial stenosis of the portal vein, and sham-operated controls (SO, n =14). Splanchnic hemodynamics was measured by radioactive microsphere techniques and the concentration of PGI2 was detected by specific radioimmunoassay for its stable hydrolysis product 6-keto-PGF1α. Semi-quantitive reverse transcriptase-polyme-rase chain reaction (RT-PCR) was performed to measure the levels of COX-1 mRNA and COX-2 mRNA in the thoracic aorta, superior mesenteric artery( SMA),and small intestine of IHPH, PHPH and SO rats, respectively. RESULTS: Hyperdynamic circulatory state was characterized by increased splanchnic blood flow and decreased splanchnic vascular resistance in IHPH and PHPH rats. The concentration of plasma 6-keto-PGF1α ( pg/ml) in IHPH (1093.75 ± 142.15) and PHPH (897. 42 ± 53. 29) rats was significantly higher than that in SO rats (730.13 ± 98. 67) (P <0.05). The expression of COX-1 mRNA in the thoracic aorta, SMA and small intestine was enhanced, whereas COX-2 mRNA expression was not detected in either of these vessels or the small intestine. The plasma 6-keto-PGF1α concentration and the expression of COX-1 mRNA in these vessels and the small intestine were closely correlated with such hemodynamic parameters as portal venous inflow (PVI), splanchnic vascular resistance (SVR) and free portal venous pressure (FPP) (P<0.05). CONCLUSION: The expression of COX-1 mRNA and the levels of PGI2 were closely related to the hyperdynamic circulatory state of portal hypertensive rats.

关键词： hypertension, portal hyperhemodynamics prostacyclin cyclooxygenase

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

引用

Cancer Communications 2024年第1期44卷 127-172页

作者： feng-hua Wang Xiao-Tian Zhang Lei Tang Qi wu Mu-Yan Cai Yuan-fang Li Xiu-Juan Qu Hong qiu Yu-Jing Zhang Jie-Er Ying Jun Zhang Ling-Yu Sun rong-Bo Lin Chang Wang Hao Liu Miao-Zhen qiu Wen-Long Guan Sheng-Xiang Rao jia-Fu Ji Yan Xin Wei-Qi Sheng hui-Mian xu zhi-Wei Zhou Ai-Ping Zhou Jing Jin Xiang-Lin Yuan feng Bi Tian-Shu Liu Han Liang Yan-Qiao Zhang Guo-Xin Li Jun Liang Bao-Rui Liu Lin Shen Jin Li Rui-hua xu department of medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer HospitalBeijingP.R.China department of Radiology Peking University Cancer HospitalBeijingP.R.China department of Endoscopy Center Peking University Cancer HospitalBeijingP.R.China department of Pathology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineGuangzhouGuangdongP.R.China department of Gastric surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China department of medical Oncology The First Hospital of China Medical UniversityShenyangLiaoningP.R.China department of medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiP.R.China department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China department of medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China department of medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R.China department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China department of medical Oncology Fujian Cancer HospitalFuzhouFujianP.R.China Tumor Center The First Hospital of Jilin UniversityChangchunJilinP.R.China department of General surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongP.R.China department of Radiology Zhongshan HospitalFudan UniversityShanghaiP.R.China department of

The 2023 update of the Chinese Society of Clinical Oncology(CSCO)Clini-cal Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in china,reflecting the latest advancements in evidence-based medicine,healthcare resource availability,and precision *** updates address the differences in epidemiological characteristics,clinicopatho-logical features,tumor biology,treatment patterns,and drug selections between Eastern and Western gastric cancer *** revisions include a structured template for imaging diagnosis reports,updated standards for molecular marker testing in pathological diagnosis,and an elevated recommendation for neoadju-vant chemotherapy in stage III gastric *** advanced metastatic gastric cancer,the guidelines introduce new recommendations for immunotherapy,anti-angiogenic therapy and targeted drugs,along with updated management strategies for human epidermal growth factor receptor 2(HER2)-positive and deficient DNA mismatch repair(dMMR)/microsatellite instability-high(MSI-H)***,the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric *** 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice,particularly in the heterogeneous healthcare landscape of china,while maintaining a commitment to scientific rigor,impartiality,and timely revisions.

关键词： Chinese Society of Clinical Oncology(CSCO) gastric cancer diagnosis surgery neoadjuvant adjuvant radiotherapy chemotherapy targeted therapy immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma:a single-center,single-arm,phase 2 study

引用

Signal Transduction and Targeted Therapy 2023年第4期8卷 1983-1992页

作者： Guo-Ming Shi Xiao-yong huang Dong wu hui-Chuan Sun Fei Liang Yuan Ji Yi Chen Guo-huan Yang jia-Cheng Lu Xian-Long meng Xin-Ying Wang Lei Sun Ning-Ling Ge Xiao-wu huang Shuang-jian qiu Xin-rong Yang Qiang Gao Yi-feng He Yang xu jian Sun Zheng-Gang Ren jia Fan jian Zhou department of Liver surgery and Transplantation Liver Cancer InstituteZhongshan HospitalFudan UniversityShanghaiChina department of Radiology Zhongshan HospitalFudan UniversityShanghaiChina department of Statistics Zhongshan HospitalFudan UniversityShanghaiChina department of Pathology Zhongshan HospitalFudan UniversityShanghaiChina department of Hepatic Oncology Liver Cancer InstituteZhongshan HospitalFudan UniversityShanghaiChina Tianjin medical Laboratory BGI-TianjinBGI ShenzhenTianjinChina

Advanced intrahepatic cholangiocarcinoma(ICC)has a dismal ***,we report the efficacy and safety of combining toripalimab,lenvatinib,and gemcitabine plus oxaliplatin(GEMOX)as first-line therapy for advanced *** patients with pathologically confirmed advanced ICC received intravenous gemcitabine(1 g/m2)on Days 1 and 8 and oxaliplatin(85 mg/m2)Q3W for six cycles along with intravenous toripalimab(240 mg)Q3W and oral lenvatinib(8 mg)once daily for one *** expression of programmed death-ligand 1(PD-L1)and genetic status was investigated in paraffin-embedded tissues using immunohistochemistry and whole-exome sequencing(WES)*** primary endpoint was the objective response rate(ORR).secondary outcomes included safety,overall survival(OS),progression-free survival(PFS),disease control rate(DCR)and duration of response(DoR).As of July 1,2022,the median follow-up time was 23.5 months,and the ORR was 80%.Twenty-three patients achieved partial response,and one achieved complete ***(21/30)with DNA damage response(DDR)-related gene mutations showed a higher ORR,while patients(14/30)with tumor area positivity≥1(PD-L1 staining)showed a trend of high ORR,but without significant *** median OS,PFS,and DoR were 22.5,10.2,and 11.0 months,*** DCR was 93.3%.Further,56.7%of patients experienced manageable grade≥3 adverse events(AEs),commonly neutropenia(40.0%)and leukocytopenia(23.3%).In conclusion,toripalimab plus lenvatinib and GEMOX are promising first-line regimens for the treatment of advanced ICC.A phase-III,multicenter,double-blinded,randomized study to validate our findings was approved by the National medical Products Administration(NMPA,No.2021LP01825).

关键词： regimen intrahepatic treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

引用

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-Liang Li Ming-Sheng huang Wei-Zhu Yang Guo-Wen Yin bin-Yan Zhong Jun-hui Sun zhi-Cheng Jin jian-jian Chen Nai-jian Ge Wen-bin Ding Wen-hui Li Jin-hua huang Wei Mu Shan-zhi Gu jia-Ping Li hui Zhao Shu-Wei Wen Yan-Ming Lei Yu-Sheng Song Chun-Wang Yuan Wei-Dong Wang Ming huang Wei Zhao jian-bing wu Song Wang xu Zhu jian-Jun Han Wei-Xin Ren Zai-Ming Lu Wen-Ge Xing yong Fan Hai-Lan Lin Zi-Shu Zhang Guo-hui xu Wen-Hao Hu Qiang Tu Hong-Ying Su Chuan-Sheng Zheng yong Chen xu-Ya Zhao Zhu-Ting fang Qi Wang Jin-Wei Zhao Ai-bing xu jian xu Qing-hua wu huan-Zhang Niu jian Wang feng Dai Dui-Ping feng Qing-Dong Li rong-Shu Shi jia-Rui Li Guang Yang Hai-bin Shi jian-Song Ji Yu-E Liu Zheng Cai Po Yang Yang Zhao Xiao-Li Zhu Li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China department of Interventional Radiology Nantong First People’s HospitalNantong 226001China department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China department of Vascular surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;Pbination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Delayed right-sided diaphragmatic hernia with severe craniocerebral trauma

引用

中华医学杂志(英文版) 2010年第7期123卷 974-976页

作者： TANG hua wu Li-hui LI jian-qiu xu zhi-fei department of Thoracic and Cardiovascular surgery Shanghai Changzheng Hospital Second Military Medical University Shanghai 200003 China）

Diaphragmatic hernia (DH) is an uncommon result oftrauma, but presents a severe problem in patientswith multiple injuries. Right-sided DH is rare, owing tothe protection of the liver and strength of the righthemidiaphragm. Here we present a case of delayedright-sided DH with severe craniocerebral *** REPORTA 45-year-old woman was involved in a car crash 14 daysbefore. Before she was transported to our emergency

关键词： trauma diaphragmatic hernia craniocerebral trauma

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-bin Ling Qiao-Nan Shan xu-yong Wei Rui Wang Chang-Ku jia Li Zhuang Tian Shen Li-Min Ding zhi-Dan xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi fang Nan jiang Kun Zhang Zhao-Jie Su zhi-Hai Peng Ren Lang Tao jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-zhi Guo Liu-Gen Lan xu-yong Sun Dong Chen zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian jian-hua Shi Bo Wang jiang Liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong wu Chang-jiang Lu Cai-De Lu Dong-hua Zhang xuan Wang Zi-Qiang Li Mu-jian Teng Jun-Jie Li Wen-Tao jiang jian-hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-hua Song zhi-Ren Fu Wei qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si bin Xie Xiao-Shun He zhi-yong Guo Shu-Sen Zheng Xiao xu department of Hepatobiliary and Pancreatic surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China department of Hepatobiliary and Pancreatic surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China department of Hepatobiliary and Pancreatic surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China department of Hepatic surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China department of General surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China department of Hepatic surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China department of Hepatobiliary and Pancreatic surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of wuhan university Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China department of Hepatobiliary surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Development of the Scientific,Transparent and Applicable Rankings (STAR) tool for clinical practice guidelines

引用

Chinese medical Journal 2023年第12期136卷 1430-1438页

作者： Nan Yang hui Liu Wei Zhao Yang Pan Xiangzheng Lyu Xiuyuan Hao Xiaoqing Liu Wen’an Qi Tong Chen Xiaoqin Wang Boheng Zhang Weishe Zhang qiu Li Dong xu Xinghua Gao Yinghui Jin feng Sun Wenbo meng Guobao Li Qijun wu Ze Chen xu Wang Janne Estill Susan LNorris Liang Du Yaolong Chen Junmin Wei Evidence-Based Medicine Center School of Basic Medical SciencesLanzhou UniversityLanzhouGansu 730000China Institute of Global Health University of GenevaGeneva 1202Switzerland School of Public Health Lanzhou UniversityLanzhouGansu 730000China Editor-in-Chief Office Chinese Medical Association Publishing HouseBeijing 100052China Marketing department Chinese Medical Association Publishing HouseBeijing 100052China Editorial department National Medical Journal of ChinaChinese Medical Association Publishing HouseBeijing 100052China Editorial department Chinese Medical JournalChinese Medical Association Publishing HouseBeijing 100052China Division of Infectious Diseases Department of Internal MedicineState Key Laboratory of Complex Severe and Rare DiseasePeking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China Editorial office of Digital Medicine and Health Chinese Medical Association Publishing HouseBeijing 100052China department of Hematology Huashan HospitalFudan UniversityShanghai 200040China Evidence-based Medicine Center Fudan UniversityShanghai 200032China department of Hepatic Oncology Xiamen Clinical Research Center for Cancer TherapyZhongshan Hospital(Xiamen)Fudan UniversityXiamenFujian 361015China department of Obstetrics Xiangya HospitalCentral South UniversityChangshaHunan 410008China department of Nephrology Children’s Hospital of Chongqing Medical UniversityNational Clinical Research Center for Child Health and DisordersMinistry of Education Key Laboratory of Child Development and DisordersChongqing Key Laboratory of PediatricsChongqing 400014China SMU Institute for Global Health(SIGHT) School of Health Management and Dermatology HospitalSouthern Medical University(SMU)GuangzhouGuangdong 510515China department of Dermatology The First Hospital of China Medical UniversityShenyangLiaoning 110001China Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWu

Background:This study aimed to develop a comprehensive instrument for evaluating and ranking clinical practice guidelines,named Scientific,Transparent and Applicable Rankings tool(STAR),and test its reliability,validity,and ***:This study set up a multidisciplinary working group including guideline methodologists,statisticians,journal editors,clinicians,and other *** review,Delphi methods,and hierarchical analysis were used to develop the STAR *** evaluated the instrument’s intrinsic and interrater reliability,content and criterion validity,and ***:STAR contained 39 items grouped into 11 *** mean intrinsic reliability of the domains,indicated by Cronbach’sαcoefficient,was 0.588(95%confidence interval[CI]:0.414,0.762).Interrater reliability as assessed with Cohen’s kappa coefficient was 0.774(95%CI:0.740,0.807)for methodological evaluators and 0.618(95%CI:0.587,0.648)for clinical *** overall content validity index was ***’s r correlation for criterion validity was 0.885(95%CI:0.804,0.932).The mean usability score of the items was 4.6 and the median time spent to evaluate each guideline was 20 ***:The instrument performed well in terms of reliability,validity,and efficiency,and can be used for comprehensively evaluating and ranking guidelines.

关键词： Practice guideline Evidence-based practice Quality control

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Delayed right-sided diaphragmatic hernia with severe ：raniocerebral trauma

引用

Chinese medical Journal 2010年第7期 974-976页

作者： TANG hua wu Li-hui LI jian-qiu xu zhi-fei department of Thoracic and Cardiovascular surgery Shanghai Changzheng Hospital Second Military Medical University Shanghai 200003 China

Diaphragmatic hernia （DH） is an uncommon result of trauma, but presents a severe problem in patients With multiple injuries. Right-sided DH is rare, owing to the protection of the liver and strength of the right hem... 详细信息

关键词： trauma diaphragmatic hernia craniocerebral trauma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study

引用

Chinese medical Journal 2021年第11期134卷 1299-1309页

作者： Yuan-Kai Shi Xiao-Nan Hong jian-Liang Yang Wei xu hui-Qiang huang Xiu-bin Xiao Jun Zhu Dao-bin Zhou Xiao-Hong Han jian-qiu wu Ming-zhi Zhang Jie Jin Xiao-Yan Ke Wei Li De-Pei wu Shen-Miao Yang Xin Du yong-Qian jia Ai-Chun Liu Dai-Hong Liu zhi-Xiang Shen Lian-Sheng Zhang Leonard James Edward Hellriegel department of medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021China department of medical Oncology Fudan University Shanghai Cancer CenterShanghai 200030China department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China department of medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China department of medical Oncology 307 Hospital of Chinese People’s Liberation ArmyBeijing 100071China department of Lymphoma Peking University Cancer Hospital&InstituteBeijing 100142China department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China department of Oncology Jiangsu Cancer Hospital&Jiangsu Institute of CancerNanjingJiangsu 210009China department of Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China department of Hematology The First Affiliated Hospital of Zhejiang University College of MedicineHangzhouZhejiang 310003China department of Hematology Peking University Third HospitalBeijing 100191China department of Oncology Jilin University First Affiliated HospitalChangchunJilin 130021China department of Hematology Jiangsu Institute of HematologyThe First Affiliated Hospital of Soochow UniversitySuzhouJiangsu 215006China department of Hematology Peking University Institute of HematologyPeking University People’s HospitalBeijing 100044China department of Hematology Guangdong General HospitalGuangzhouGuangdong 510062China department of Hematology and Research Laboratory of Hematology West China Hospital of Sichuan UniversityChengduSichuan 610041China department of medical Oncology Harbin Medical University Cancer HospitalHarbinHeilongjiang 150001China department of Hematolo

Background:Bendamustine was approved in china on May 26th,2019 by the National medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma(NHL).The current study was the registration trial and the first reported evaluation of the efficacy,safety,and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab ***:This was a prospective,multicenter,open-label,single-arm,phase 3 study(NCT01596621;C18083/3076)with a 2-year follow-up *** patients received bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles(and up to eight cycles).The primary endpoint was the overall response rate(ORR);and secondary endpoints were duration of response(DoR),progression-free survival(PFS),safety,and *** were classified according to their best overall response after initiation of *** of patients in each response category(complete response[CR],partial response[PR],stable disease,or progressive disease)were summarized along with a twosided binomial exact 95%confidence intervals(CIs)for the ***:A total of 102 patients were enrolled from 20 centers between August 6th,2012,and June 18th,*** the time of the primary analysis,the ORR was 73%(95%CI:63%–81%)per Independent Review Committee(IRC)including 19%CR and 54%*** the follow-up period,the median DoR was 16.2 months by IRC and 13.4 months by investigator assessment;the median PFS was 18.6 months and 15.3 months,*** most common non-hematologic adverse events(AEs)were gastrointestinal toxicity,pyrexia,and *** 3/4 neutropenia was reported in 76%of *** AEs were reported in 29 patients and five patients died during the *** analysis indicated that the characteristics of bendamustine and its metabolites M3 and M4 were generally consistent

关键词： Bendamustine Non-Hodgkin lymphoma B-cell malignancy Relapsed disease Clinical trial

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

基于个体化机器学习的原发性免疫性血小板减少症危重出血预测模型:一项全国前瞻性队列研究

引用

科学通报:英文版 2023年第18期68卷 2106-2114,M0004页

作者： Zhuo-Yu An Ye-Jun wu Yu Hou Heng Mei Wei-Xia Nong Wen-Qian Li Hu Zhou Ru feng jian-Ping Shen Jun Peng Hai Zhou Yi Liu yong-Ping Song Lin-hua Yang Mei-Yun fang jian-yong Li Yun-feng Cheng Peng Liu Ya-Jing xu Zhao Wang Yi Luo Zhen Cai hui Liu Jing-Wen Wang Juan Li Xi Zhang Zi-Min Sun Xiao-Yu Zhu Xin Wang rong Fu Liang huang Shao-Yuan Wang Tong-hua Yang Li-Ping Su Liang-Ming Ma Xie-Qun Chen Dai-Hong Liu Hong-Xia Yao jia feng Hong-Yu Zhang Ming jiang Ze-Ping Zhou Wen-Sheng Wang xu-Liang Shen Yangjin Baima Yue-Ying Li Qian-Fei Wang qiu-Sha huang Hai-Xia Fu Xiao-Lu Zhu Yun He Qian jiang Hao jiang Jin Lu Xiang-Yu Zhao Ying-Jun Chang Tao wu Yao-Zhu Pan Lin qiu Da Gao A-rong Jin Wei Li Su-Jun Gao Lei Zhang Ming Hou Xiao-Jun huang Xiao-hui Zhang on behalf of the National Cooperative ITP Working Group Peking university People’s hospital Peking University Institute of HematologyBeijing 100044China Collaborative Innovation Center of Hematology Peking UniversityBeijing 100044China Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing 100044China National Clinical Research Center for Hematologic Disease Beijing 100044China department of Hematology Qilu HospitalCheeloo College of MedicineShandong UniversityJinan 250014China Institute of Hematology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430074China department of Hematology First Affiliated HospitalSchool of MedicineShihezi UniversityShihezi 832002China department of Hematology Qinghai Provincial People’s HospitalXining 810007China Henan Cancer hospital Affiliated Cancer Hospital of Zhengzhou UniversityHenan Institute of HematologyZhengzhou 450008China department of Hematology Beijing HospitalBeijing 100044China department of Hematology Zhejiang Provincial Hospital of Traditional Chinese MedicineHangzhou 310006China department of Hematology Senior Department of Hematologythe Fifth Medical Center of PLA General HospitalBeijing 100044China department of Hematology the Second Hospital of Shanxi Medical UniversityTaiyuan 030001China department of Hematology Affiliated Zhongshan Hospital of Dalian UniversityDalian 116001China department of Hematology The First Affiliated Hospital with Nanjing Medical University(Jiangsu Province Hospital)Nanjing 210029China department of Hematology Zhongshan HospitalFudan UniversityShanghai 200032China department of Hematology Xiangya HospitalCentral South UniversityChangsha 410008China department of Hematology Beijing Friendship HospitalCapital Medical UniversityBeijing 100044China Institute of Hematology the First Affiliated HospitalZhejiang UniversityHangzhou 310058China department of Hematology Beijing Tongren HospitalBeijing 100005China department of Hematology The First Affiliated HospitalSun Yat-sen UniversityGuang

原发性免疫性血小板减少症(ITP)中少见但至关重要的危重出血事件,给患者的预后、生活质量和治疗决策带来严重影响。尽管有一些研究探讨了ITP中与危重出血相关的风险因素,但目前尚缺乏大样本数据、大规模多中心研究结果以及针对ITP患者... 详细信息

原发性免疫性血小板减少症(ITP)中少见但至关重要的危重出血事件,给患者的预后、生活质量和治疗决策带来严重影响。尽管有一些研究探讨了ITP中与危重出血相关的风险因素,但目前尚缺乏大样本数据、大规模多中心研究结果以及针对ITP患者致命出血事件的预测模型。本研究首次采用国际血栓与止血学会新提出的ITP致命出血标准,利用大样本数据开发了首个基于机器学习的在线应用,用于预测ITP患者的致命出血.研究中,我们使用中国各地大型多中心数据进行开发,并对全国39家医疗中心进行为期一年的外部测试,得到了较好的训练、验证和测试数据集预测能力该基于新算法的便捷网络工具能够快速识别ITP患者的出血风险,辅助临床决策,有望未来降低不良事件的发生。

关键词： Critical bleeding Severe bleeding Immune thrombocytopenia Machine learning Prediction model

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：